{"prompt": "['CONFIDENTIAL', '204878 (ZOSTER-064)', 'Protocol Administrative Change 3 Final', '13. REFERENCES', '45', '11-FEB-2019', '15', '70882527ffe6806e42bab9a20b06541da11028ce']['CONFIDENTIAL', '204878 (ZOSTER-064)', 'Protocol Administrative Change 3 Final', 'LIST OF TABLES', 'PAGE', 'Table 1', 'List of study procedures', '28', 'Table 2', 'Construction of the eight scales generated from the SF-36', '35', 'Table 3', 'Detail of frailty components', '35', '11-FEB-2019', '16', '70882527ffe6806e42bab9a20b06541da11028ce']['CONFIDENTIAL', '204878 (ZOSTER-064)', 'Protocol Administrative Change 3 Final', 'LIST OF ABBREVIATIONS', 'ATP', 'According to protocol', 'BOI', 'Burden of illness', 'EQ-5D', 'EuroQol 5D questionnaire', 'GCP', 'Good Clinical Practice', 'GSK', 'GlaxoSmithKline', 'HZ', 'Herpes Zoster', 'HZ/su', 'Herpes Zoster Subunit Vaccine (50g gE/AS01B)', 'HZAC', 'Herpes Zoster Ascertainment Committee', 'ICH', 'International Conference on Harmonisation', 'IEC', 'Independent Ethics Committee', 'IND', 'Investigational New Drug', 'IRB', 'Institutional Review Board', 'mTVC', 'modified Total Vaccinated Cohort', 'PCR', 'Polymerase Chain Reaction', 'PHN', 'Postherpetic Neuralgia', 'QoL', 'Quality of Life', 'SDV', 'Source Document Verification', 'SF-36', 'Short Form 36 Questionnaire', 'TTO', 'Time-Trade-Off', 'TVC', 'Total Vaccinated Cohort', 'VZV', 'Varicella-Zoster Virus', 'YOA', 'Years of Age', 'ZBPI', 'Zoster Brief Pain Inventory', '11-FEB-2019', '18', '70882527ffe6806e42bab9a20b06541da11028ce']\n\n###\n\n", "completion": "END"}